%0 Journal Article
%T Determinants of hemorrhagic risk during acenocoumarol treatment
%A Florentina C. Militaru
%A Sorin Cri£¿an
%A £¿tefan C. Vesa
%A Adrian Trifa
%J Human & Veterinary Medicine
%D 2012
%I Bioflux Society
%X Objective: to determine the frequency of haemorrhage occurrence in the analysed batch; to establish the relation between the hemorrhagicrisk and the presence of supratherapeutic INR; to assess the concomitant therapy¡¯s impact on the haemorrhage risk¡¯; to study the impactof the age and sex on the hemorrhagic risk; to assess the relation between the polymorphisms of the CYP2C9 & VKORC1 genes and theoccurrence of hemorrhages. Material and Methods: The study included 223 patients (110 females (49.3%) and 113 males (50.7%)) who weretreated with acenocoumarol for one or several of the following clinic situations: 1. deep vein thrombosis (DVT) of the lower limb ¡À pulmonarythromboembolism; 2. persistent or permanent atrial fibrillation (AF) ¡À pulmonary thromboembolism. Results: Bleeding complications wereregistered in 11 patients (4.9%). The presence of a supratherapeutic INR increases the risk of bleeding complications by 3.1 times. Conclusion:our study shows that only the supratherapeutic INR was correlated with the occurrence of haemorrhages.
%K acenocoumarol
%K hemorrhagic risk
%K INR
%K polymorphisms of the CYP2C9 & VKORC1 genes
%U http://www.hvm.bioflux.com.ro/docs/HVM_4.1.5.pdf